US · AZTA · MEDICAL - INSTRUMENTS & SUPPLIES
Azenta, Inc. (AZTA) intrinsic value and stock valuation
$44.80as of 2026-11-21 · Mkt cap 1.48B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Azenta, Inc. DCF and intrinsic value
InvestorsCraft values AZTA with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from AZTA’s statements →
Azenta, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $593.8M | $573.5M | $665.1M | $555.5M | $513.7M |
| Operating income | -$-11.27M | -$-29.98M | -$-82.2M | -$-24.02M | $3.6M |
| Net income | -$-55.76M | -$-164.9M | -$-14.26M | -$-428.96M | $110.8M |
| EPSd | -$-1.21M | -$-3.1M | -$-215.25K | -$-5.73M | $1.49M |
| Operating cash flow | $72.2M | $49.7M | $5.83M | -$-466.05M | $149.9M |
| Capital expenditure | -$-33.86M | -$-37.39M | -$-39.44M | -$-77.44M | -$-52.8M |
| Free cash flow | $38.3M | $12.4M | -$-33.6M | -$-543.48M | $97.1M |
| Total assets | $2.06B | $2.1B | $2.89B | $3.72B | $1.82B |
| Total debt | $111.2M | $70.7M | $60.4M | $49.2M | $94.8M |
| Net debt | -$-168.61M | -$-240.25M | -$-618.47M | -$-609.05M | -$-132.66M |
| Total equity | $1.73B | $1.77B | $2.53B | $3.36B | $1.33B |
| Cash and short-term investments | $340.9M | $462.1M | $1.02B | $1.57B | $227.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $593.8M | $573.5M | $665.1M | $555.5M | $513.7M |
| Cost of revenue | $323.5M | $318.8M | $431.8M | $324.9M | $299.2M |
| Gross profit | $270.3M | $254.6M | $233.3M | $230.6M | $214.5M |
| Research and development expenses | $30.4M | $31.5M | $34M | $27.5M | $22.4M |
| Selling, general and administrative expenses | $251.2M | $253.1M | $281.5M | $227.1M | $188.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $281.6M | $284.6M | $315.5M | $254.6M | $210.9M |
| Cost and expenses | $605.1M | $603.4M | $747.3M | $579.5M | $510.1M |
| Interest income | $18.8M | $33.2M | $43.7M | $20.3M | $630K |
| Interest expense | $0.00 | $0.00 | $0.00 | $4.59M | $2.04M |
| Depreciation and amortization | $61.2M | $90.7M | $85.6M | $53.7M | $56.9M |
| Ebitda | $54.1M | $71.6M | $55.2M | $48.4M | $9.94M |
| Operating income | -$-11.27M | -$-29.98M | -$-82.2M | -$-24.02M | $3.6M |
| Total other income/expenses, net | $4.12M | $10.9M | $51.8M | $14.1M | -$-52.56M |
| Income before tax | -$-7.14M | -$-19.12M | -$-30.43M | -$-9.94M | -$-48.97M |
| Income tax expense | -$-31.6M | $5.24M | -$-17.55M | $1.35M | -$-20.1M |
| Net income | -$-55.76M | -$-164.9M | -$-14.26M | -$-428.96M | $110.8M |
| Weighted average shares outstanding | $45.7M | $53.2M | $66.3M | $74.9M | $74.2M |
| Weighted average diluted shares outstanding | $45.9M | $53.2M | $66.3M | $74.9M | $74.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $340.9M | $462.1M | $1.02B | $1.57B | $227.5M |
| Net receivables | $189.2M | $172.7M | $156.5M | $163.8M | $119.9M |
| Inventory | $75M | $115.3M | $128.2M | $85.5M | $60.4M |
| Total current assets | $708.3M | $832.8M | $1.42B | $2.46B | $777.4M |
| Property, plant and equipment, net | $208M | $266.7M | $205.7M | $154.5M | $130.7M |
| Goodwill and intangible assets | $804.2M | $939.4M | $1.08B | $692M | $655.9M |
| Long-term investments | $247.2M | $49.5M | $111.3M | $352M | $3.6M |
| Total non-current assets | $1.35B | $1.27B | $1.47B | $1.26B | $1.04B |
| Total assets | $2.06B | $2.1B | $2.89B | $3.72B | $1.82B |
| Accounts payable | $37.7M | $44.4M | $35.8M | $38.7M | $42.4M |
| Short-term debt | $7.78M | $10.6M | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $32.6M | $32M | $34.6M | $39.8M | $25.7M |
| Total current liabilities | $237.7M | $204.8M | $210.9M | $230.6M | $345.1M |
| Long-term debt | $103.4M | $60.1M | $60.4M | $49.2M | $94.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $93M | $126.2M | $140.3M | $122.2M | $149.1M |
| Capital lease obligations | $52.2M | $70.7M | $60.4M | $49.2M | $45.1M |
| Total liabilities | $330.7M | $331.1M | $351.2M | $352.7M | $494.2M |
| Common stock | $590K | $590K | $710K | $890K | $880K |
| Retained earnings | $1.42B | $1.48B | $1.64B | $1.66B | -$-470.05M |
| Accumulated other comprehensive income (loss) | -$-22.21M | -$-13.46M | -$-62.43M | -$-83.92M | $19.4M |
| Total equity | $1.73B | $1.77B | $2.53B | $3.36B | $1.33B |
| Total investments | $308.3M | $200.6M | $450.2M | $1.26B | $3.68M |
| Total debt | $111.2M | $70.7M | $60.4M | $49.2M | $94.8M |
| Net debt | -$-168.61M | -$-240.25M | -$-618.47M | -$-609.05M | -$-132.66M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-55.76M | -$-164.9M | -$-14.64M | $2.13B | $110.8M |
| Depreciation and amortization | $61.2M | $90.7M | $85.6M | $53.7M | $65.3M |
| Stock-based compensation | $20.9M | $14.5M | $9.38M | $10.7M | $27.5M |
| Change in working capital | -$-22.84M | $3.04M | -$-29.04M | -$-72.73M | -$-51.21M |
| Accounts receivable | -$-24.56M | -$-12.07M | $34.5M | -$-31.4M | -$-69.64M |
| Inventory | -$-2.67M | $15.9M | $8.25M | -$-66.63M | -$-50.44M |
| Accounts payable | $1.04M | $9.2M | -$-14.71M | -$-3.93M | $31M |
| Net cash provided by operating activities | $72.2M | $49.7M | $5.83M | -$-466.05M | $149.9M |
| Investments in property, plant and equipment | -$-33.86M | -$-37.39M | -$-39.44M | -$-73.44M | -$-52.8M |
| Acquisitions, net | $0.00 | $0.00 | -$-386.51M | $2.81B | -$-95.51M |
| Net cash used for investing activities | -$-90.46M | $224.7M | $431.4M | $1.47B | -$-146.35M |
| Common stock issued | $2.77M | $3.28M | $3.62M | $5.25M | $5.81M |
| Common stock repurchased | $0.00 | -$-661.7M | -$-838.51M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | -$-7.49M | -$-29.73M |
| Net cash used for financing activities | -$-9.59M | -$-659.21M | -$-840.46M | -$-62.76M | -$-25.91M |
| Net change in cash | -$-24.3M | -$-363.06M | -$-357.25M | $756M | -$-17.19M |
| Cash at end of period | $296.7M | $321M | $684M | $1.04B | $285.3M |
| Operating cash flow | $72.2M | $49.7M | $5.83M | -$-466.05M | $149.9M |
| Capital expenditure | -$-33.86M | -$-37.39M | -$-39.44M | -$-77.44M | -$-52.8M |
| Free cash flow | $38.3M | $12.4M | -$-33.6M | -$-543.48M | $97.1M |
Line items
Line items
Line items
About Azenta, Inc.
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
- CEO
- John Marotta
- Employees
- 3K
- Beta
- 1.37
Explore
Frequently asked questions
What is the intrinsic value of Azenta, Inc. (AZTA)?
Azenta, Inc. (AZTA) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AZTA undervalued?
AZTA trades at a price of $44.80 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.